Angiotensin-Converting Enzyme Inhibitors in Coronary Artery Disease and Preserved Left Ventricular Systolic Function
A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Mouaz H. Al-Mallah, MD*,*,
Imad M. Tleyjeh, MD ,
Ahmed A. Abdel-Latif, MD and
W. Douglas Weaver, MD, FACC*
* Division of Cardiology, Henry Ford Heart and Vascular Institute, Detroit, Michigan
Department of Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota
Division of Cardiology, University of Louisville, Louisville, Kentucky
View larger version (21K):
[in a new window]
|
Figure 1 Search strategy results. RCT = randomized controlled trials.
|
|
View larger version (41K):
[in a new window]
|
Figure 2 Pooled data from the included trials. The angiotensin-converting enzyme inhibitor (ACEI) therapy was associated with a decrease in cardiovascular (CV) death (A), all-cause mortality (B), revascularization (C), and nonfatal myocardial infarction (MI) (D). CAMELOT = Effect of Antihypertensive Agents on Cardiovascular Events in Patients With Coronary Disease and Normal Blood Pressure Trial; EUROPA = European Trial on Reduction of Cardiac Events With Perindopril in Stable Coronary Arteries trial; HOPE = Heart Outcomes Prevention Evaluation trial; PART-2 = Prevention of Atherosclerosis With Ramipril Trial; PEACE = Angiotensin-Converting Enzyme Inhibition in Stable Coronary Artery Disease; QUIET = Quinapril Ischemic Event Trial; RR = relative risk.
|
|
|
